Study of TGI-5 alone or with nivolumab for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing, Skin clinical trials.
This trial tests a new drug called TGI-5, either by itself or combined with another drug (nivolumab), for people with advanced cancer that hasn't responded to standard treatments. It's looking for patients with certain types of solid tumors, especially colorectal, melanoma, lung, or others that have stopped responding to therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have an advanced solid tumor that is not curable by surgery and has spread, and that has gotten worse despite standard treatments or you cannot tolerate those treatments
- Your tumor must have a specific protein called PD-L1 at a certain level (at least 1% positive) for the second part of the study
- You must have at least one tumor that can be measured on scans and hasn't been treated with radiation recently
- Your overall health must be good enough for daily activities (ECOG score 0-2)
- Your blood work (kidney, liver, and blood cell counts) must meet minimum levels
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new study drug, GV20-0251, for people with advanced solid tumors that no longer respond to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug, GV20-0251, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and helpful.
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
This trial tests GC101 tumor-infiltrating lymphocytes (TILs), which are special immune cells collected from a tumor, grown in a lab, and given back to treat gastrointestinal cancers that have returned or spread. It may help your immune system better attack the cancer, especially when standard treatments have not worked.
This study tests a new drug called TGI-6 in people with advanced solid tumors, including colorectal cancer and other cancers that have a specific marker (B7-H6). The goal is to see if it is safe and effective for those who have run out of standard treatment options.
This trial tests an experimental treatment called VET3-TGI, which is injected directly into tumors. It is for people with advanced solid tumors who have already tried other treatments and are looking for new options.
Hear when a new Melanoma (Skin Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.